Evidence map›Paper›PMID 37865395›Full record

ArticleJournal for immunotherapy of cancer2023

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.

Nurudeen A Adegoke, Tuba N Gide, Yizhe Mao, Camelia Quek, Ellis Patrick, Matteo S Carlino, Serigne N Lo, Alexander Maxwell Menzies, Ines Pires da Silva, Ismael A Vergara and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06536257 (Personalised Immunotherapy Platform), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06536257 recruitingnot on this map

Personalised Immunotherapy Platform (PIP) - Implementation of a Predictive Model of Response to Immunotherapies in Melanoma

TypeobservationalSponsorMelanoma Institute AustraliaRan2021 to 2037Enrolled1,000ConditionsMelanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell CarcinomaArmsPredictive model
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Tumorous IRE1α facilitates CD8Cell communication and signaling : CCS · 2024
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Nurudeen A AdegokeMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-7592-5460
Tuba N GideMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Yizhe MaoMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Camelia QuekMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Ellis PatrickCentre for Cancer Research, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.ORCID 0000-0002-5253-4747
Matteo S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Serigne N LoMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-5092-5544
Alexander Maxwell MenziesMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Ines Pires da SilvaMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3540-8906
Ismael A VergaraMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Georgina LongMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-8894-3545
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-8991-0013
James S WilmottMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia james.wilmott@sydney.edu.au.ORCID 0000-0002-6750-5244
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor microenvironment (TME) characteristics are potential biomarkers of response to immune checkpoint inhibitors in metastatic melanoma. This study developed a method to perform unsupervised classification of TME of metastatic melanoma.

methodsWe used multiplex immunohistochemical and quantitative pathology-derived assessment of immune cell compositions of intratumoral and peritumoral regions of metastatic melanoma baseline biopsies to classify TME in relation to response to anti-programmed cell death protein 1 (PD-1) monotherapy or in combination with anti-cytotoxic T-cell lymphocyte-4 (ipilimumab (IPI)+PD-1).

resultsSpatial profiling of CD8+T cells, macrophages, and melanoma cells, as well as phenotypic PD-1 receptor ligand (PD-L1) and CD16 proportions, were used to identify and classify patients into one of three mutually exclusive TME classes: immune-scarce, immune-intermediate, and immune-rich tumors. Patients with immune-rich tumors were characterized by a lower proportion of melanoma cells and higher proportions of immune cells, including higher PD-L1 expression. These patients had higher response rates and longer progression-free survival (PFS) than those with immune-intermediate and immune-scarce tumors. At a median follow-up of 18 months (95% CI: 6.7 to 49 months), the 1-year PFS was 76% (95% CI: 64% to 90%) for patients with an immune-rich tumor, 56% (95% CI: 44% to 72%) for those with an immune-intermediate tumor, and 33% (95% CI: 23% to 47%) for patients with an immune-scarce tumor. A higher response rate was observed in patients with an immune-scarce or immune-intermediate tumor when treated with IPI+PD-1 compared with those treated with PD-1 alone.

conclusionsOur study provides an automatic TME classification method that may predict the clinical efficacy of immunotherapy for patients with metastatic melanoma.

Indexed as

B7-H1 AntigenMelanomaHumansImmunotherapyIpilimumabProgrammed Cell Death 1 ReceptorTumor MicroenvironmentB7-H1 AntigenIpilimumabProgrammed Cell Death 1 ReceptorImmunotherapyMelanomaPATHOLOGYTumor Microenvironment

Identifiers

PMID37865395
PMCPMC10603328
OpenAlexW4387850021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.